Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS (MEDICAID)

Fentanyl Transmucosal IR Agents (TIRF) (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-855-684-5250**.

When conditions are met, we will authorize the coverage of Fentanyl Transmucosal IR Agents (TIRF) (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug	Name (please circle)				
Abstral (fentanyl sublingual tablets) Lazanda (fentanyl citrate nasal spray)		Fentora (fentanyl buccal tablets)	fentanyl citrate lozenges		
		Subsys (fentanyl sublingual spray)			
Othe	r, please specify				
Quantity Route of Administration		Frequency	Strength _		
		Expected Length of therapy			
Pati	ent Information				
Patie	nt Name:				
Patie	nt ID:				
Patie	nt Phone:				
Pres	scribing Physician				
Phys	ician Name:				
Specialty:		NPI Number:			
Physician Fax:		Physician Phone:			
Physician Address:		City, State, Zip:			
Diag	nosis:	ICD Code:			_
Pleas	e circle the appropriate answer for e	each question.			
1.		orized this medication in the past for orization is on file under this plan)?		Υ	N
	[If no, then skip to question 4.]				
2.	Has the patient had improvem	ent in breakthrough cancer pain?		Υ	N
	[If no, then no further question	s.]			
3.	Is the patient continuing the us the-clock while on treatment?	se of a long-acting opioid around-		Υ	N

Reference Number: C11433-C/ Effective Date: 12/01/2017

	[No further questions.]		
4.	Is the requested drug being prescribed by or in consultation with an oncologist or pain specialist?	Υ	N
	[If no, then no further questions.]		
5.	Does the patient have the diagnosis of cancer?	Υ	Ν
	[If no, then no further questions.]		
6.	Will treatment be used for breakthrough cancer pain?	Υ	Ν
	[If no, then no further questions.]		
7.	Is the patient taking a long-acting opioid around-the-clock for treatment of cancer pain?	Υ	N
	[If no, then no further questions.]		
8.	Is the patient considered to be opioid-tolerant, having received at least ONE WEEK of treatment on ONE of the following medications: A) Morphine sulfate at doses of at least 60 mg/day, B) Fentanyl transdermal patch at doses of at least 25 mcg/hour, C) Oxycodone at doses of at least 30 mg/day, D) Oral hydromorphone at doses of at least 8 mg/day, E) An alternative opioid at an equianalgesic dose for at least a week (e.g., oral methadone at doses of at least 20 mg/day)?	Υ	N
	[If no, then no further questions.]		
9.	Is this request for generic fentanyl citrate lozenges?	Υ	Ν
	[If no, then skip to question 11.]		
10	. Is the patient 16 years of age or older?	Υ	Ν
	[No further questions.]		
11	.Has the patient experienced an inadequate response or intolerance to generic fentanyl citrate lozenges?	Υ	N
	[If no, then no further questions.]		

Reference Number: C11433-C/ Effective Date: 12/01/2017

Prescriber (Or Authorized) Signature Date			
I affirm that the information given on this form is true and accurate as of this date.			
Comments:			
12. Is the patient 18 years of age or older?	Y	N	

Reference Number: C11433-C/ Effective Date: 12/01/2017